Allergy Therapeutics plc announced that Nick Wykeman, Chief Financial Officer has tendered his resignation, with effect from November 30, 2022, in order to pursue non-executive roles. Nick Wykeman, who has been a Director of Allergy Therapeutics for six years, remains in his role for six months and a search for his successor will now commence.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.4 GBX | 0.00% | +7.94% | +36.00% |
1st Jan change | Capi. | |
---|---|---|
+36.00% | 206M | |
+8.63% | 115B | |
+13.17% | 107B | |
-12.76% | 22.31B | |
-3.99% | 21.6B | |
-7.19% | 18.23B | |
-39.93% | 17.62B | |
+6.67% | 14.26B | |
+33.90% | 12.37B | |
-28.60% | 8.28B |
- Stock Market
- Equities
- AGY Stock
- News Allergy Therapeutics plc
- Allergy Therapeutics plc Announces Resignation of Nick Wykeman as Chief Financial Officer, effective from November 30, 2022